At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Trading 08-14 14:42:46 EDT
1.02
-0.15
-12.74%
High1.12Low0.9942Vol381.08K
Open1.12D1 Closing1.17Amplitude10.75%
Mkt Cap16.31MTradable Cap9.94MTotal Shares15.98M
T/O395.68KT/O Rate3.92%Tradable Shares9.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tempest Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14 05:44
Tempest Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Tempest Therapeutics Enters USD 50 Million Equity Purchase Deal with Lincoln Park Capital Fund
Reuters  ·  08-14 04:39
Tempest Therapeutics Enters USD 50 Million Equity Purchase Deal with Lincoln Park Capital Fund
Tempest Therapeutics - Enters $50 Mln Common Stock Purchase Agreement with Lincoln Park - SEC Filing
THOMSON REUTERS  ·  08-14 04:34
Tempest Therapeutics - Enters $50 Mln Common Stock Purchase Agreement with Lincoln Park - SEC Filing
Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  08-14 04:25
Press Release: Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics Inc Expected to Post a Loss of 30 Cents a Share - Earnings Preview
Reuters  ·  08-07
Tempest Therapeutics Inc Expected to Post a Loss of 30 Cents a Share - Earnings Preview
Tempest Therapeutics Partners with Senlang Biotech to Advance Tpst-4003 in Vivo CAR-T into First-in-human Trial
Reuters  ·  07-21
Tempest Therapeutics Partners with Senlang Biotech to Advance Tpst-4003 in Vivo CAR-T into First-in-human Trial
Tempest Announces Development Collaboration with Senlang Biotechnology for Tpst-4003, a Cd7-targeted Next-generation in Vivo CAR-T
THOMSON REUTERS  ·  07-21
Tempest Announces Development Collaboration with Senlang Biotechnology for Tpst-4003, a Cd7-targeted Next-generation in Vivo CAR-T
Tempest Therapeutics - Co and Senlang to Develop Tpst-4003 with Trial in China for Mg and MS
THOMSON REUTERS  ·  07-21
Tempest Therapeutics - Co and Senlang to Develop Tpst-4003 with Trial in China for Mg and MS
Tempest Therapeutics - First Patient Dosing for Tpst-4003 Trial Expected in Q4 2026
THOMSON REUTERS  ·  07-21
Tempest Therapeutics - First Patient Dosing for Tpst-4003 Trial Expected in Q4 2026
How Jakarta Plans to End Open Dumping in Bantargebang
Tempo  ·  07-18
How Jakarta Plans to End Open Dumping in Bantargebang
Tempest Therapeutics Plans First Clinical Study of in Vivo CAR-T Candidate Tpst-4003 in Q4 2026
Reuters  ·  07-15
Tempest Therapeutics Plans First Clinical Study of in Vivo CAR-T Candidate Tpst-4003 in Q4 2026
Rani Therapeutics Names Nicholas Maestas CFO, Replacing Svai Sanford
Reuters  ·  06-29
Rani Therapeutics Names Nicholas Maestas CFO, Replacing Svai Sanford
Tempest Therapeutics Registers 2.43 Million Shares for Resale
MT Newswires Live  ·  06-27
Tempest Therapeutics Registers 2.43 Million Shares for Resale
Tempest Therapeutics - Selling Stockholders May Offer up to 2.43 Mln Shares of Tempest Therapeutics Common Stock - SEC Filing
THOMSON REUTERS  ·  06-27
Tempest Therapeutics - Selling Stockholders May Offer up to 2.43 Mln Shares of Tempest Therapeutics Common Stock - SEC Filing
Jakarta Offers Prizes for Waste Sorting on Anniversary Peak Night
Tempo  ·  06-25
Jakarta Offers Prizes for Waste Sorting on Anniversary Peak Night
Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12
Reuters  ·  06-24
Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12
Tempest Therapeutics shareholders approved Nasdaq Rule 5635 share issuances at special meeting
Reuters  ·  06-23
Tempest Therapeutics shareholders approved Nasdaq Rule 5635 share issuances at special meeting
Tempest Therapeutics director John D. Yee files initial beneficial ownership statement
Reuters  ·  06-18
Tempest Therapeutics director John D. Yee files initial beneficial ownership statement
Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement
Reuters  ·  06-09
Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement
Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing
THOMSON REUTERS  ·  06-05
Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--